

**Notification of Termination of Agreement Concerning  
Co-promotion of Fosamac<sup>®</sup>**

This is a notification that MSD (Headquarters: Chiyoda-ku, Tokyo; Company President: Tony Alvarez; hereinafter referred to as “MSD”) and Hisamitsu Pharmaceutical Co., Inc. (Headquarters: Tosu City, Saga Prefecture; Company President: Hirotaka Nakatomi; hereinafter referred to as “Hisamitsu”), having undertaken co-promotional activities between the two companies from March 2009 regarding Fosamac<sup>®</sup> (Nonproprietary name: Alendronate sodium), which is manufactured and sold by MSD, have decided to terminate this partnership on the last day of February 2012, in accordance with the expiry of the term of the agreement.

MSD shall continue to undertake the activities for the supply and collection of pharmaceutical product information on Fosamac<sup>®</sup>, which to date have been carried out by Hisamitsu in accordance with the terms of this agreement. In addition, from October 2011 onward, the two companies shall start to provide guidance on this matter to medical institutions.

In addition, the influence that this matter gives in the consolidated results of both companies is slight.